Literature DB >> 24382388

Clinical development of demethylating agents in hematology.

Shyamala C Navada, Juliane Steinmann, Michael Lübbert, Lewis R Silverman.   

Abstract

The term epigenetics refers to the heritable changes in gene expression that are not associated with a change in the actual DNA sequence. Epigenetic dysregulation is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. DNA methylation is frequently altered in cancerous cells and likely results in transcriptional silencing of tumor suppressor genes. Re-expression of these genes by inhibition of the DNA methyltransferases has been successful in the treatment of benign and malignant disease. In this Review, we discuss the clinical development of demethylating agents in hematology, with a focus on azacitidine and decitabine.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24382388      PMCID： PMC3871232          DOI： 10.1172/JCI69739

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  60 in total

1.  5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.

Authors:  A Pinto; V Zagonel; V Attadia; P L Bullian; V Gattei; A Carbone; S Monfardini; A Colombatti
Journal:  Bone Marrow Transplant       Date:  1989-12       Impact factor: 5.483

2.  Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.

Authors:  G E Rivard; R L Momparler; J Demers; P Benoit; R Raymond; K Lin; L F Momparler
Journal:  Leuk Res       Date:  1981       Impact factor: 3.156

3.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

4.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

Authors:  Alice B Kornblith; James E Herndon; Lewis R Silverman; Erin P Demakos; Rosalie Odchimar-Reissig; James F Holland; Bayard L Powell; Carlos DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; Jimmie C Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 5.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

6.  Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.

Authors:  P W Wijermans; J W Krulder; P C Huijgens; P Neve
Journal:  Leukemia       Date:  1997-01       Impact factor: 11.528

7.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Authors:  P Wijermans; M Lübbert; G Verhoef; A Bosly; C Ravoet; M Andre; A Ferrant
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

Authors:  L R Silverman; J F Holland; R S Weinberg; B P Alter; R B Davis; R R Ellison; E P Demakos; C J Cornell; R W Carey; C Schiffer
Journal:  Leukemia       Date:  1993-05       Impact factor: 11.528

9.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.

Authors:  T J Ley; J DeSimone; N P Anagnou; G H Keller; R K Humphries; P H Turner; N S Young; P Keller; A W Nienhuis
Journal:  N Engl J Med       Date:  1982-12-09       Impact factor: 91.245

10.  Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Authors:  Thomas Prebet; Zhuoxin Sun; Maria E Figueroa; Rhett Ketterling; Ari Melnick; Peter L Greenberg; James Herman; Mark Juckett; Mitchell R Smith; Lisa Malick; Elisabeth Paietta; Magdalena Czader; Mark Litzow; Janice Gabrilove; Harry P Erba; Steven D Gore; Martin S Tallman
Journal:  J Clin Oncol       Date:  2014-03-24       Impact factor: 44.544
View more
  56 in total

Review 1.  Epigenetics in myelodysplastic syndromes.

Authors:  Michael Heuser; Haiyang Yun; Felicitas Thol
Journal:  Semin Cancer Biol       Date:  2017-08-02       Impact factor: 15.707

2.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

Authors:  David Roulois; Helen Loo Yau; Rajat Singhania; Yadong Wang; Arnavaz Danesh; Shu Yi Shen; Han Han; Gangning Liang; Peter A Jones; Trevor J Pugh; Catherine O'Brien; Daniel D De Carvalho
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

3.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Authors:  Grégory Ehx; Gilles Fransolet; Laurence de Leval; Stéphanie D'Hondt; Sophie Lucas; Muriel Hannon; Loïc Delens; Sophie Dubois; Pierre Drion; Yves Beguin; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

Review 4.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

Review 5.  Prospects for the development of epigenetic drugs for CNS conditions.

Authors:  Moshe Szyf
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

6.  Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.

Authors:  Jihao Zhou; Yushi Yao; Qi Shen; Guoqiang Li; Lina Hu; Xinyou Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-20       Impact factor: 4.553

7.  Transcriptional Selectivity of Epigenetic Therapy in Cancer.

Authors:  Takahiro Sato; Matteo Cesaroni; Woonbok Chung; Shoghag Panjarian; Anthony Tran; Jozef Madzo; Yasuyuki Okamoto; Hanghang Zhang; Xiaowei Chen; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2016-11-22       Impact factor: 12.701

8.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

Review 9.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

10.  Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.

Authors:  Guillermo Garcia-Manero; Elizabeth A Griffiths; David P Steensma; Gail J Roboz; Richard Wells; James McCloskey; Olatoyosi Odenike; Amy E DeZern; Karen Yee; Lambert Busque; Casey O'Connell; Laura C Michaelis; Joseph Brandwein; Hagop Kantarjian; Aram Oganesian; Mohammad Azab; Michael R Savona
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.